Qubit Pharmaceuticals specializes in ‘in silico’ drug discovery for challenging disease targets, including those currently viewed as being ‘undruggable’ using small molecules by the pharmaceutical community.

Their approach is using proprietary molecular simulation and quantum-physics based modeling technology built from over 30 years of research from Pr. Jay W. Ponder’s lab in Washington University in St. Louis, Pr. Pengyu’s Ren lab in University of Texas at Austin, Pr. Jean-Philip Piquemal and Docteur Louis Lagardère at Sorbonne University, and Pr. Matthieu Montes at the Conservatoire national des arts et métiers (Cnam).

Qubit Pharma uses a hybrid approach leveraging the power of both classical and quantum computing to produce more effective and safer drugs and is designed to significantly reduce the time and investment needed to discover new drug candidates by a factor of 10.

Today, the focus lies on solving cancer resistance and escapement, a growing concern in aging populations, and chronic inflammatory diseases. Qubit Pharma is well positioned to become one of the first companies to show a practical quantum advantage in drug discovery.

In less than 18 months, Qubit Pharmaceuticals grew its drug discovery portfolio to 6 programs in oncology & inflammation leveraging its proprietary drug discovery platform, Atlas.

Qubit Pharma out-licenses and co-develops compounds with pharmaceutical partners. Once our candidate compounds have achieved advanced stages of drug development, we may seek out-licensing and other strategic alliances for further development, manufacturing, and launching the drug as a commercial pharmaceutical product in selective geographies.

–  Therapeutic areas: Solving cancer resistance and escapement, a growing concern in aging populations, and chronic inflammatory diseases

–  Based in: Paris (FRANCE) & Boston (USA)

–  Employees: 51 – 200

–  Created in: 2020